BidaskClub cut shares of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) from a hold rating to a sell rating in a report issued on Friday morning.

A number of other equities analysts have also recently weighed in on AIMT. Zacks Investment Research raised Aimmune Therapeutics from a sell rating to a buy rating and set a $21.00 price objective on the stock in a report on Tuesday, May 16th. ValuEngine cut Aimmune Therapeutics from a hold rating to a sell rating in a report on Saturday, May 27th. Wedbush reissued an outperform rating and set a $42.00 price objective on shares of Aimmune Therapeutics in a report on Monday, July 24th. Finally, Piper Jaffray Companies set a $38.00 price objective on Aimmune Therapeutics and gave the company a buy rating in a report on Thursday, July 27th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus target price of $33.00.

Shares of Aimmune Therapeutics (AIMT) opened at 19.12 on Friday. Aimmune Therapeutics has a 12-month low of $12.38 and a 12-month high of $27.31. The stock’s 50 day moving average price is $20.96 and its 200 day moving average price is $19.94. The company’s market capitalization is $966.23 million.

Aimmune Therapeutics (NASDAQ:AIMT) last announced its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.64) by $0.01. On average, equities research analysts forecast that Aimmune Therapeutics will post ($2.68) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This article was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://www.thecerbatgem.com/2017/08/14/aimmune-therapeutics-inc-aimt-downgraded-by-bidaskclub.html.

In related news, insider Stephen George Dilly sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $21.46, for a total transaction of $1,073,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Susan E. Barrowcliffe sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $20.26, for a total value of $303,900.00. Following the transaction, the insider now owns 15,000 shares in the company, valued at $303,900. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 188,470 shares of company stock worth $3,942,092. 24.56% of the stock is owned by corporate insiders.

A number of institutional investors have recently bought and sold shares of AIMT. State Street Corp raised its position in Aimmune Therapeutics by 50.5% in the fourth quarter. State Street Corp now owns 576,147 shares of the biotechnology company’s stock valued at $11,782,000 after buying an additional 193,272 shares during the last quarter. Swiss National Bank raised its position in Aimmune Therapeutics by 17.5% in the first quarter. Swiss National Bank now owns 36,974 shares of the biotechnology company’s stock valued at $803,000 after buying an additional 5,500 shares during the last quarter. Renaissance Technologies LLC bought a new position in Aimmune Therapeutics during the fourth quarter valued at about $2,100,000. Palo Alto Investors LLC raised its position in Aimmune Therapeutics by 209.0% in the first quarter. Palo Alto Investors LLC now owns 1,173,498 shares of the biotechnology company’s stock valued at $25,500,000 after buying an additional 793,771 shares during the last quarter. Finally, Norges Bank bought a new position in Aimmune Therapeutics during the fourth quarter valued at about $1,258,000. Institutional investors and hedge funds own 69.65% of the company’s stock.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Receive News & Stock Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related stocks with our FREE daily email newsletter.